PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
June 20, 2026Journal of the American College of Cardiology157 citationsOpen Access

Human Cardiac Progenitor Cells Engineered With Pim-I Kinase Enhance Myocardial Repair

View Full Paper
SMSadia MohsinMKMohsin KhanHTHaruhiro Toko

Key Points

  • The aim is to enhance the repair and regenerative abilities of human cardiac progenitor cells through genetic modification for myocardial infarction treatment.
  • hCPCs isolated from heart failure patients are genetically modified to express GFP or Pim-1-GFP.
  • Functional tests conducted with immunocompromised mice via intramyocardial injection post-infarction.
  • Monitoring of myocardial function through echocardiography and hemodynamic assessments for 20 weeks post-delivery.
  • hCPCeP show significantly increased proliferation and improved hemodynamic performance at 20 weeks after transplantation.
  • Enhanced differentiation and engraftment of hCPCeP were observed, with better vasculature and reduced infarct size compared to hCPCe.
  • Persistence of hCPCeP is maintained up to 8 weeks post-delivery as shown by bioluminescence imaging.

Abstract

Objective Enhancement of human cardiac progenitor cell (hCPC) reparative and regenerative potential by genetic modification for treatment of myocardial infarction. Background Regenerative potential of stem cells to repair acute infarction is limited. Improved hCPC survival, proliferation and differentiation into functional myocardium will increase efficacy and advance translational implementation of cardiac regeneration. Methods hCPCs isolated from myocardium of heart failure patients undergoing left ventricular assist device (LVAD) implantation are engineered to express green fluorescent protein (GFP; hCPCe) or Pim-1-GFP (hCPCeP). Functional tests of hCPC regenerative potential are performed with immunocompromised mice by intramyocardial adoptive transfer injection after infarction. Myocardial structure and function is monitored by echocardiographic and hemodynamic assessment for 20 weeks following delivery. hCPCe and hCPCeP expressing luciferase are followed by bioluminesence imaging (BLI) to non-invasively track persistence. Results hCPCeP exhibit augmentation of reparative potential relative to hCPCe control cells as demonstrated by significantly increased proliferation coupled with amelioration of infarction injury and increased hemodynamic performance at 20 weeks post-transplantation. Concurrent with enhanced cardiac structure and function, hCPCeP demonstrate increased cellular engraftment and differentiation with improved vasculature and reduced infarct size. Enhanced persistence of hCPCeP versus hCPCe is revealed by BLI at up to 8 weeks post delivery. Conclusion Genetic engineering of hCPCs with Pim-1 enhances repair of damaged myocardium. Ex vivo gene delivery to modify stem cells has emerged as a viable option addressing current limitations in the field. This study demonstrates that efficacy of human CPCs from the failing myocardium can be safely and significantly enhanced through expression of Pim-1 kinase, setting the stage for use of engineered cells in preclinical settings.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Mohsin et al. (2012) studied this question.

synapsesocial.com/papers/6a3606a7dace31c64cd34966https://doi.org/10.1016/j.jacc.2012.04.047
Ask AI
Helpful
Bookmark
Share
View Full Paper